Providing early antiretroviral drug treatment for recently infected HIV patients and their uninfected sexual partners is a cost-effective way to help patients stay healthy and prevent transmission of HIV, a new study finds.
During the first five years of the study, 93% of those who received early antiretroviral therapy survived, compared with 83% of those whose treatment was delayed. Life expectancy was nearly 16 years for those in the early treatment group, compared with nearly 14 years for those in the delayed treatment group.
Study done in SA
"HIV-infected patients live healthier lives, their partners are protected from HIV, and the investment is superb," she added.